PATENT COOPERATION TREATY

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter I of the Patent Cooperation Treaty)

(PCT Rule 44bis)

Applicant's or agent's file reference 3223WO0P	FOR FURTHER ACTION	See item 4 below	
International application No. PCT/US2005/013583	International filing date (day/month/year) 06 April 2005 (06.04.2005)	Priority date (day/month/year) 07 April 2004 (07.04.2004)	
International Patent Classification (8th See relevant information in Form F	n edition unless older edition indicated) PCT/ISA/237	•	
Applicant TAKEDA PHARMACEUTICAL CO	MPANY LIMITED		

1.	 This international preliminary report on patentability (Chapter I) is issued by the International Bureau on behalf of the International Searching Authority under Rule 44 bis. 1(a). 			
2.				
	In the attached sheets, any reference to the written opinion of the International Searching Authority should be read as a reference to the international preliminary report on patentability (Chapter I) instead.			
3.	3. This report contains indications relating to the following items:			
	Box No. I Basis of the report			
Box No. II Priority				
	Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability			
	Box No. IV	Lack of unity of invention		
	Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement		
	Box No. VI	Certain documents cited		
	Box No. VII	Certain defects in the international application		
	Box No. VIII	Box No. VIII Certain observations on the international application		
4.	4. The International Bureau will communicate this report to designated Offices in accordance with Rules 44bis.3(c) and 93bis.1 but not, except where the applicant makes an express request under Article 23(2), before the expiration of 30 months from the priority date (Rule 44bis.2).			
			Date of issuance of this report 01 May 2007 (01.05.2007)	
The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland		ombettes	Authorized officer Simin Baharlou	
	Facsimile No. +41 22 338 82 70 e-mail: pt09.pct@wipo.int			
-	DCT/IB/373 (January 2004)			

PATENT COOPERATION TREATY From the INTERNATIONAL SEARCHING AUTHORITY PCT MARK CHAO TAKEDA PHARMACEUTICALS NORTH AMERICA, INC. 475 HALF DAY ROAD WRITTEN OPINION OF THE LINCOLNSHIRE, IL 60069 INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis. 1) Date of mailing (day/month/year) FOR FURTHER ACTION Applicant's or agent's file reference See paragraph 2 below 3223WO0P Priority date (day/month/year) International filing date (day/month/year) International application No. 06 April 2005 (06.04.2005) 07 April 2004 (07.04.2004) PCT/US05/13583 International Patent Classification (IPC) or both national classification and IPC Please See Continuation Sheet 544/297,262,253,105,236,237;546/153,138,118;514/230.5,248,266.1,275,266.4,300,306,312 USPC: Applicant TAKEDA PHARMACEUTICAL COMPANY LIMITED 1. This opinion contains indications relating to the following items: Box No. I Basis of the opinion Box No. II Priority Non-establishment of opinion with regard to novelty, inventive step and industrial applicability Box No. III Box No. IV Lack of unity of invention Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement Box No. VI Certain documents cited Box No. VII Certain defects in the international application Certain observations on the international application Box No. VIII 2. FURTHER ACTION If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

3. For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA/ US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Date of completion of this opinion

21 December 2006 (21.12.2006)

Telephone No. 571-272-1600

Form PCT/ISA/237 (cover sheet) (April 2005)

Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/US05/13583

DOX 11.	A Dasis of this opinion
	egard to the language, this opinion has been established on the basis of:
\boxtimes	the international application in the language in which it was filed
	a translation of the international application into, which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
2. With inven	regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed tion, this opinion has been established on the basis of:
8.	type of material
	a sequence listing
	table(s) related to the sequence listing
b .	format of material
	on paper
	in electronic form
C.	time of filing/furnishing
	contained in the international application as filed.
	filed together with the international application in electronic form.
	furnished subsequently to this Authority for the purposes of search.
3. 🗌	In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4. Additi	onal comments:
	· ·
•	
	·
	·
	·
	*
	· # \$ * * * * * * * * * * * * * * * * * *
orm PCT	ISA/237(Box No. I) (April 2005)

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

Form PCT/ISA/237 (Box No. V) (April 2005)

International application No. PCT/US05/13583

Box No. V Reasoned statement under Rule 43 bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
1. Statement				
Novelty (N)	Claims 1-21	v	ES	
•	Claims NONE	N		
Inventive step (IS)	Claims · <u>1-21</u>			
	Claims NONE		ES O	
Industrial applicability (IA)	. Claims <u>1-21</u>			
manual applicationity (111)	Claims NONE	Y.	ES O	
2. Citations and explanations:	· · · · · · · · · · · · · · · · · · ·	·····		
Claims 1-21 meet the criteria set out in PCT Article 33 compounds recited in claim 1 such as the 4H-Pyrrolo[2	(2)-(3), because the prior art does in 2,3-d]pyrimidin-4-one derivatives of	not teach or fairly suggest the instant or the 4H-quinolizin-4-one derivatives.		
Claims 1-21 meet the criteria set out in PCT Article 33 because the subject matter claimed can be made or used	(4) and thus the compounds of the		,	
			•	
•	·	•		
•		•		
·				
• .				
	•			
		,	-	

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/US05/13583

Supplemental Box In case the space in a	ny of the preceding boxes is	not sufficient				
Continuation of IPC	1),221/02(2006.01),239/22(2 5.01),31/519(2006.01),31/538			A61K 31/52(20	06.01),31/4704(2	006.01),31/505(
					٠٠٠ پر	
						2
					1	
						07
				•		
					•	
	•					
					10	
•			•			
	•					•
				•		
•			•			
						•